Is Inovio Pharmaceuticals Stock a Good Investment?
Inovio Pharmaceuticals Investment Advice | INO |
- Examine Inovio Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Inovio Pharmaceuticals' leadership team and their track record. Good management can help Inovio Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Inovio Pharmaceuticals' business and its evolving consumer preferences.
- Compare Inovio Pharmaceuticals' performance and market position to its competitors. Analyze how Inovio Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Inovio Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Inovio Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Inovio Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Inovio Pharmaceuticals is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Inovio Pharmaceuticals Stock
Researching Inovio Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 34.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.44. Some equities with similar Price to Book (P/B) outperform the market in the long run. Inovio Pharmaceuticals recorded a loss per share of 4.43. The entity had not issued any dividends in recent years. The firm had 1:12 split on the 25th of January 2024.
To determine if Inovio Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Inovio Pharmaceuticals' research are outlined below:
| Inovio Pharmaceuticals generated a negative expected return over the last 90 days | |
| Inovio Pharmaceuticals has high historical volatility and very poor performance | |
| Inovio Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 832.01 K. Reported Net Loss for the year was (135.12 M) with loss before taxes, overhead, and interest of (177.39 M). | |
| Inovio Pharmaceuticals has about 348.13 M in cash with (124.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.4. | |
| Inovio Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Inovio Pharmaceuticals SWOT analysis biotech stock faces hurdles amid pipeline progress |
Inovio Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Inovio Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Inovio Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Inovio Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Inovio Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-10 | 2023-03-31 | -0.14 | -0.16 | -0.02 | 14 | ||
2015-03-16 | 2014-12-31 | -0.1 | -0.12 | -0.02 | 20 | ||
2014-11-10 | 2014-09-30 | -0.14 | -0.12 | 0.02 | 14 | ||
2019-08-08 | 2019-06-30 | -0.27 | -0.3 | -0.03 | 11 | ||
2018-11-08 | 2018-09-30 | -0.3 | -0.27 | 0.03 | 10 | ||
2016-05-09 | 2016-03-31 | -0.14 | -0.11 | 0.03 | 21 | ||
2015-11-09 | 2015-09-30 | 0.04 | 0.07 | 0.03 | 75 | ||
2015-08-10 | 2015-06-30 | -0.13 | -0.1 | 0.03 | 23 |
Know Inovio Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Inovio Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Inovio Pharmaceuticals backward and forwards among themselves. Inovio Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Inovio Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Qube Research & Technologies | 2024-06-30 | 79.3 K | Charles Schwab Investment Management Inc | 2024-09-30 | 71.1 K | Nuveen Asset Management, Llc | 2024-06-30 | 46.5 K | Goldman Sachs Group Inc | 2024-06-30 | 42.4 K | American Century Companies Inc | 2024-09-30 | 40.8 K | Rhumbline Advisers | 2024-06-30 | 38.5 K | Bank Of America Corp | 2024-06-30 | 38.4 K | Two Sigma Investments Llc | 2024-06-30 | 37.6 K | Green Alpha Advisors, Llc | 2024-06-30 | 33.1 K | Deep Track Capital, Lp | 2024-09-30 | 1.8 M | Vanguard Group Inc | 2024-09-30 | 1.8 M |
Inovio Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 106.23 M.Market Cap |
|
Inovio Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.78) | (0.82) | |
| Return On Capital Employed | (1.04) | (1.09) | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | (1.15) | (1.21) |
Determining Inovio Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Inovio Pharmaceuticals is a good buy. For example, gross profit margin measures Inovio Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Inovio Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Inovio Pharmaceuticals' management efficiency
Inovio Pharmaceuticals has Return on Asset of (0.3991) % which means that on every $100 spent on assets, it lost $0.3991. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.9142) %, meaning that it generated no profit with money invested by stockholders. Inovio Pharmaceuticals' management efficiency ratios could be used to measure how well Inovio Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of November 2024, Return On Tangible Assets is likely to drop to -0.82. In addition to that, Return On Capital Employed is likely to drop to -1.09. At this time, Inovio Pharmaceuticals' Non Current Assets Total are very stable compared to the past year. As of the 24th of November 2024, Other Current Assets is likely to grow to about 6.9 M, while Total Assets are likely to drop about 131.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.29 | 4.28 | |
| Tangible Book Value Per Share | 5.29 | 3.73 | |
| Enterprise Value Over EBITDA | (1.16) | (1.22) | |
| Price Book Value Ratio | 1.16 | 1.10 | |
| Enterprise Value Multiple | (1.16) | (1.22) | |
| Price Fair Value | 1.16 | 1.10 | |
| Enterprise Value | 322.2 M | 306.1 M |
Leadership effectiveness at Inovio Pharmaceuticals is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 0.833 |
Basic technical analysis of Inovio Stock
As of the 24th of November, Inovio Pharmaceuticals retains the Standard Deviation of 3.34, market risk adjusted performance of (0.41), and Risk Adjusted Performance of (0.19). Inovio Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Inovio Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Inovio Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Inovio Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Inovio Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Inovio Pharmaceuticals' Outstanding Corporate Bonds
Inovio Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Inovio Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Inovio bonds can be classified according to their maturity, which is the date when Inovio Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| Iris Merger Sub Corp BondUS45774NAB47 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Inovio Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Inovio Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.19) | |||
| Market Risk Adjusted Performance | (0.41) | |||
| Mean Deviation | 2.38 | |||
| Coefficient Of Variation | (396.45) | |||
| Standard Deviation | 3.34 | |||
| Variance | 11.18 | |||
| Information Ratio | (0.29) | |||
| Jensen Alpha | (1.10) | |||
| Total Risk Alpha | (1.38) | |||
| Treynor Ratio | (0.42) | |||
| Maximum Drawdown | 17.45 | |||
| Value At Risk | (7.07) | |||
| Potential Upside | 3.22 | |||
| Skewness | (0.66) | |||
| Kurtosis | 1.9 |
| Risk Adjusted Performance | (0.19) | |||
| Market Risk Adjusted Performance | (0.41) | |||
| Mean Deviation | 2.38 | |||
| Coefficient Of Variation | (396.45) | |||
| Standard Deviation | 3.34 | |||
| Variance | 11.18 | |||
| Information Ratio | (0.29) | |||
| Jensen Alpha | (1.10) | |||
| Total Risk Alpha | (1.38) | |||
| Treynor Ratio | (0.42) | |||
| Maximum Drawdown | 17.45 | |||
| Value At Risk | (7.07) | |||
| Potential Upside | 3.22 | |||
| Skewness | (0.66) | |||
| Kurtosis | 1.9 |
Consider Inovio Pharmaceuticals' intraday indicators
Inovio Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Inovio Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Inovio Pharmaceuticals Corporate Filings
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 13th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 1st of July 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Inovio Stock media impact
Far too much social signal, news, headlines, and media speculation about Inovio Pharmaceuticals that are available to investors today. That information is available publicly through Inovio media outlets and privately through word of mouth or via Inovio internal channels. However, regardless of the origin, that massive amount of Inovio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Inovio Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Inovio Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Inovio Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Inovio Pharmaceuticals alpha.
Inovio Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Inovio Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Inovio Pharmaceuticals Corporate Management
| Asli Gevgilili | Chief Officer | Profile | |
| Jeffrey Skolnik | Senior Development | Profile | |
| Robert Juba | Senior Management | Profile | |
| E MBA | Senior Assurance | Profile | |
| MBA MA | Senior Development | Profile | |
| Ben Matone | Director Relations | Profile | |
| Laurent Humeau | Chief Scientific Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.43) | Revenue Per Share 0.025 | Quarterly Revenue Growth (0.55) | Return On Assets (0.40) | Return On Equity (0.91) |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Inovio Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.